Checkpoint inhibitors for the treatment of advanced hepatocellular carcinoma
Published: 12 Jun 2020
Views: 391
Dr Katie Kelley - University of California San Francisco, San Francisco, USA
Dr Katie Kelley talks to ecancer in an online interview for the ASCO virtual meeting 2020 about using durvalumab and tremelimumab for the treatment of advanced hepatocellular carcinoma.
She initially gives a thorough description of the trial design and rationale for the four study arms.
Dr Kelley proceeds to detail the results and whether the endpoints were met, and also some interesting outcomes from the biomarker analyses.
She looks forward to new data coming out, including the HIMALAYA trial.
Related Videos
Five year update of ECHELON-1 for classical Hodgkin lymphoma
Dr Otavio Baiocchi - Centro Especializado em Oncologia, São Paulo, Brazil
8 Dec 2020
Bevacizumab-induced hypertension and proteinuria: A genome-wide analysis of more...
Prof Federico Innocenti - University of North Carolina, Chapel Hill, USA
4 Nov 2020
PARP inhibitors and their evolving role for the treatment of prostate cancer
Dr Neal Shore, Dr Neeraj Agarwal, Dr Elena Castro and Dr Kim Chi
24 Sep 2020
IMvigor130: Atezolizumab with or without chemotherapy in metastatic urothelial c...
Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA
30 Jun 2020
Checkmate 9LA: Nivolumab, ipilimumab and chemotherapy for stage IV NSCLC
Prof Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany
30 Jun 2020
Cisplatin plus/minus veliparib in metastatic TNBC and/or germline BRCA-associate...
Dr Julie Gralow - University of Washington School of Medicine, Seattle, USA
29 May 2020
PROMISE-meso trial results: Pembrolizumab vs chemotherapy for advanced pleural m...
Prof Sanjay Popat - The Royal Marsden Hospital, London, UK
7 Oct 2019
PARP inhibitors for metastatic breast cancer
Prof Michael Untch - Helios Hospital Berlin-Buch, Berlin, Germany
7 Oct 2019
Latest data from KEYNOTE 42: Pembrolizumab vs chemotherapy in treatment-naive pa...
Prof Tony Mok - Chinese University of Hong Kong, Hong Kong
18 Apr 2019
